FDA cites Jiangsu Meifan Biotechnology for OTC drug manufacturing-rule failures and import alert.
What happened
FDA reviewed records Jiangsu Meifan Biotechnology submitted after an August 15, 2022 FDA request for records, not an inspection. FDA found the company did not show adequate finished-drug testing, including active ingredient identity and strength, and that its quality unit did not effectively oversee manufacturing quality. FDA placed the firm on Import Alert 66-40 on April 1, 2024, which can stop U.S. entry of its products.
What FDA found
The firm did not show it performed adequate finished-product testing for each batch, including identity and strength of active ingredients, before release.
21 CFR 211.165(a)The firm’s quality unit did not effectively exercise its authority to approve or reject all components, containers, closures, in-process materials, packaging, labeling, and drug products.
21 CFR 211.22(a)
What FDA wants
Respond in writing within 15 working days with what you did to correct violations and prevent recurrence; if you cannot complete corrective actions in that time, state why and give a completion schedule. FDA also recommends a qualified consultant and a full audit before resuming U.S. drug manufacturing.
Who should pay attention
- brands that buy OTC wipes or hand sanitizer from this contract manufacturer
- U.S. importers and distributors of Chinese OTC drug products
- companies relying on this firm’s quality records or quality-unit oversight
This is a summary. Read the original letter on fda.gov.